• Medincell will hold its annual general meeting in Jacou on Sept. 30, 2026.
• Shareholders will vote on approval of FY 2025-2026 parent and consolidated accounts, profit allocation.
• Proposed election of independent director Elisabeth Svanberg, a pharmaceutical industry executive.
• Other items include related-party agreements, executive pay and board compensation envelope, refreshed remuneration policies.
• Board sought authorizations for potential capital reductions or increases, share cancellations, issuance of securities giving access to equity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260908457402) on September 08, 2026, and is solely responsible for the information contained therein.